QNRX: Quoin Pharma Company Aggregate Debts

Symbol and logo of brand quoinpharma.com (QNRX)

Quoin Pharmaceuticals (QNRX) is attracting leading biochemists to develop treatments for rare skin pathologies by offering them generous stock options. This strategy supports the creation of innovative therapies for Netherton syndrome, which is confirmed by the price history on the GURU.Markets chart, where the metric stands at 0.00. Business efficiency is being enhanced through robotic tissue permeability tests that accelerate product launches.

QNRX: Quoin Pharmaceuticals Ltd Company Debts 07/04/2022 - 10/31/2026

Quoin Pharmaceuticals (QNRX) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart quoinpharma.com|QNRX - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Quoin Pharma|QNRX - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Quoin Pharmaceuticals|QNRX - Company Book Value|Market Cap to Net Assets Ratio quoinpharma.com|QNRX - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Quoin Pharmaceuticals|QNRX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital quoinpharma.com|QNRX - Company Debts|Debts to Net Assets Quoin Pharma|QNRX - Company Long-Term Debt|Company Short-Term Debts Quoin Pharmaceuticals|Interim Coverage Ratio quoinpharma.com
- earnings and valuation multiples information:
QNRX - Company Net Income
Fundamental company analysis:QNRX, Quoin Pharmaceuticals Ltd
Signature product of Quoin Pharmaceuticals Ltd.

Developing unique gels for the therapy of rare dermatological conditions requires colossal expenditures to pass rigorous FDA oversight. The total volume of debt capital accumulates all external obligations of Quoin Pharmaceuticals (QNRX), demonstrating a balance between financial stability and aggressive investment in patents. An analysis of total liabilities on GURU.Markets allows for an assessment of default risk relative to the capitalization potential of orphan products.

Competitors of Quoin Pharmaceuticals

KRYS (Krystal Biotech Corp.) - Aggregate Debt Obligations|Company Aggregate Debts APGE (Apogee Therapeutics)|Company Aggregate Debts arcutis.com ARQT|VCEL - Company Debts|Aggregate Debt Obligations ORKA (Oruka Therapeutics, Inc.)|sanaramedtech.com (SMTI) - Company Debts|Company Total Debt DBV Technologies|SLSN (Solesence Beauty) - Company Aggregate Debts|Company Aggregate Debts Journey Medical Corp.|Company Total Debt FBRX (Forte Biosciences)|EMPG (Empro Group Inc.) - Aggregate Debt Obligations|Company Debts Sol-Gel SLGL|Company Total Debt Obligations AXIL Brands Inc (AXIL)|MDCX - Company Debts|VRCA - Company Aggregate Debts|HOTH: Company Aggregate Debts|BFRI - Company Total Debt Obligations|Company Debts VYNE Therapeutics, Inc.|Company Aggregate Debt SNOA (Sonoma Pharma)|Company Debts Azitra, Inc. (AZTR)|dermatarx.com (DRMA) - Company Total Indebtedness|Elevai Labs - Company Total Debt|Company Aggregate Debts Revance Therapeutics Inc. RVNC